Omeros’ Omidria Revenues Grow 71 Percent

August 11, 2017: By Jon Swedien

OMEROSRevenues from Omidria grew 71 percent in Q2-2017 compared with Q2-2016, Seattle-based Omeros reported Aug. 8.

Omidria’s revenues during the quarter totaled $17.2 million, which marked a 40 percent increase over the drug’s revenues in Q1-2017, Omeros said. All of Omeros’ Q2-2017 revenues came from Omidria sales.

Omeros said units shipped by wholesalers in Q2-2017 increased 113 percent over Q2-2016 and 34 percent over Q1-2017.

Launched in April 2015, Omidria is intended for use during cataract surgery to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain. It is a combination of a mydriatic agent and a nonsteroidal anti-inflammatory agent that is added to irrigation solution used during IOL procedures.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022